These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1806 related articles for article (PubMed ID: 28167507)

  • 1. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 2. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.
    Wang Y; Zheng K; Xiong H; Huang Y; Chen X; Zhou Y; Qin W; Su J; Chen R; Qiu H; Yuan X; Wang Y; Zou Y
    Front Immunol; 2021; 12():762989. PubMed ID: 34975854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
    Orecchioni S; Talarico G; Labanca V; Calleri A; Mancuso P; Bertolini F
    Br J Cancer; 2018 May; 118(10):1329-1336. PubMed ID: 29695766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
    Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK Inhibition Remodels the Immune Landscape of Mutant
    Yang B; Li X; Fu Y; Guo E; Ye Y; Li F; Liu S; Xiao R; Liu C; Lu F; Huang J; Qin T; Han L; Peng G; Mills GB; Sun C; Chen G
    Cancer Res; 2021 May; 81(10):2714-2729. PubMed ID: 33589518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niraparib enhances antitumor immunity and contributes to the efficacy of PD-L1 blockade in cervical cancer.
    Chang J; Quan S; Tian S; Wang S; Li S; Guo Y; Yang T; Yang X
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):304. PubMed ID: 38869633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
    Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W
    Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
    Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
    Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
    [No Abstract]   [Full Text] [Related]  

  • 14. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 17. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.